Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

The Future of MSL Training – How Digital Technologies Are Shaping Success

Discover how pharmaceutical companies are using asynchronous platforms and microlearning to eliminate geographical barriers, track performance, and achieve cost-effective, consistent training for global teams.

Impetus Digital

- PMLiVE

J&J receives positive NICE recommendation for multiple myeloma treatment

The treatment is approved for use within the NHS in England and Wales

- PMLiVE

Younger, not invisible: rewriting cancer care – starting with the pancreas

By Sommer Bazuro

- PMLiVE

VML Portugal appoints Managing Director

Mariana Marta dos Santos is appointed as managing director

- PMLiVE

Women Leaders Rewriting the Protocols of Rare Disease Care

The true measure of a medical leader is the courage to act when existing systems fail the patient. This is the professional and personal ethos of clinical immunologist Dr. Hilary...

Medscape Education

- PMLiVE

The Power of the Pivot: How Nurse Practitioners are Closing Care Gaps for Women

The career path of a Nurse Practitioner is often envisioned as a straight line: clinical practice, specialization, perhaps a supervisory role. But for two pioneering NPs, Laura Demuth and Jackie...

Medscape Education

- PMLiVE

Voices of Change: Women Leading the Menopause Movement

For decades, menopause has been swept under the rug, or into the dark corners of clinicians’ offices, often dismissed as something women just had to “get past” and hardly worth...

Medscape Education

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

Medscape Wins Anthem Award for Rare Disease Education Platform

Platform has reached 2.4 million healthcare professionals worldwide since 2021. Newark, NJ - [November 18, 2025] - Medscape, the leading digital platform for physicians and healthcare professionals (HCPs), has been...

Medscape Education

- PMLiVE

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links